Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 10.98 (-2.31%)
ESPR : 2.11 (-4.52%)
CRSP : 51.88 (+2.29%)
LSTA : 2.91 (-0.34%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 10.98 (-2.31%)
AVIR : 3.44 (-3.91%)
CRSP : 51.88 (+2.29%)
APLS : 28.74 (-0.31%)
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...

BEAM : 26.10 (-1.95%)
FOLD : 10.98 (-2.31%)
AVIR : 3.44 (-3.91%)
CRSP : 51.88 (+2.29%)
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

FOLD : 10.98 (-2.31%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

FOLD : 10.98 (-2.31%)
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 10.98 (-2.31%)
AMRN : 0.5755 (-2.84%)
ARDX : 6.38 (-1.69%)
ATNM : 1.8300 (-5.18%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 10.98 (-2.31%)
CORT : 54.30 (+0.13%)
ARDX : 6.38 (-1.69%)
ATNM : 1.8300 (-5.18%)
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

FOLD : 10.98 (-2.31%)
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...

FOLD : 10.98 (-2.31%)
CRSP : 51.88 (+2.29%)
VRNA : 38.18 (+1.57%)
EXEL : 35.80 (+0.82%)
BPMC : 101.39 (+1.77%)

Barchart Exclusives

1 Energy Dividend Stock That Just Hiked Its Cash Flow Forecast
Analysts are optimistic about this dividend-paying energy company, which raised its cash flow forecast after surging LNG demand pushed it past Q3 expectations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar